Biosulin P, 100 me/ml 3 ml 3 ml cartridges in Biomatikpen syringe pens 5 pcs

Pharmaceutical group:

Hypoglycemic agent – short-acting insulin.

Pharmic action:

Biosulin® P is human insulin produced using recombinant DNA technology. It is a preparation of short-acting insulin. It interacts with specific receptor of outer cytoplasmic cell membrane and forms insulin-receptor complex, which stimulates intracellular processes, including synthesis of several key enzymes (hexokinase, pyruvate kinase, glycogen synthetase and others). Decrease of glucose content in blood is caused by an increase of its intracellular transport, increased absorption and assimilation by tissues, stimulation of lipogenesis, glycogenogenesis, decrease of glucose production rate by liver, etc.

The duration of action of insulin drugs is mainly due to the speed of absorption, which depends on several factors (e.g. on the dose, route and place of administration), so the action profile of insulin is subject to significant variations both in different people and in the same person.

The profile of action when injected subcutaneously (approximate figures): onset of action after 30 minutes, maximum effect between 2 and 4 hours, duration of action — 6-8 hours.

Pharmacokinetics:

The completeness of absorption and onset of effect of insulin depends on the route of administration (subcutaneous, intramuscular), site of administration (stomach, thigh, buttocks), dose (volume of insulin administered), insulin concentration in the drug, etc.

The distribution in tissues is uneven: it does not penetrate through the placental barrier and into the breast milk. It is broken down by insulinase mainly in the liver and kidneys. The elimination half-life is a few minutes. It is excreted by the kidneys (30-80%).

Indications

Diabetes mellitus type 1 (insulin dependent)
Diabetes mellitus type 2 (non-insulin dependent): stage of resistance to oral hypoglycemic agents, partial resistance to these drugs (with combination therapy), intercurrent diseases
Emergency conditions in patients with diabetes mellitus, accompanied by decompensation of carbohydrate metabolism.

Pharmacological effect

Pharmaceutical group:

hypoglycemic agent – short-acting insulin.

Pharmaceutical action:

Biosulin® R is human insulin obtained using recombinant DNA technology. It is a short-acting insulin preparation. It interacts with a specific receptor on the outer cytoplasmic membrane of cells and forms an insulin-receptor complex that stimulates intracellular processes, including the synthesis of a number of key enzymes (hexokinase, pyruvate kinase, glycogen synthetase, etc.). The decrease in blood glucose levels is due to an increase in its intracellular transport, increased absorption and assimilation by tissues, stimulation of lipogenesis, glycogenogenesis, a decrease in the rate of glucose production by the liver, etc.

The duration of action of insulin preparations is mainly determined by the rate of absorption, which depends on several factors (for example, dose, route and site of administration), and therefore the insulin action profile is subject to significant fluctuations, both between different people and within the same person.

Action profile for subcutaneous injection (approximate figures): onset of action after 30 minutes, maximum effect between 2 and 4 hours, duration of action 6-8 hours.

Pharmacokinetics:

The completeness of absorption and the onset of the effect of insulin depends on the method of administration (subcutaneous, intramuscular), injection site (abdomen, thigh, buttocks), dose (volume of insulin administered), insulin concentration in the drug, etc.

It is distributed unevenly throughout the tissues: it does not penetrate the placental barrier and into breast milk. It is destroyed by insulinase mainly in the liver and kidneys. The half-life is several minutes. Excreted by the kidneys (30-80%).

Special instructions

Do not use Biosulin® R if it has become cloudy, colored, or if solid particles are detected.
During insulin therapy, constant monitoring of blood glucose levels is necessary.

The causes of hypoglycemia, in addition to insulin overdose, can be: replacing the drug, skipping meals, vomiting, diarrhea, increasing physical activity, diseases that reduce the need for insulin (impaired liver and kidney function, hypofunction of the adrenal cortex, pituitary gland or thyroid gland), changing the injection site, as well as interactions with other drugs.

Incorrect dosing or interruptions in insulin administration, especially in patients with type 1 diabetes, can lead to hyperglycemia. Typically, the first symptoms of hyperglycemia develop gradually, over several hours or days. They include the appearance of thirst, increased urination, nausea, vomiting, dizziness, redness and dryness of the skin, dry mouth, loss of appetite, and the smell of acetone in the exhaled air. If left untreated, hyperglycemia in type 1 diabetes can lead to life-threatening diabetic ketoacidosis.

The dose of insulin must be adjusted in case of dysfunction of the thyroid gland, Addison’s disease, hypopituitarism, impaired liver and kidney function, and diabetes mellitus in people over 65 years of age.

Adjustment of the insulin dose may also be required if the patient increases the intensity of physical activity or changes the usual diet.

Concomitant illnesses, especially infections and conditions accompanied by fever, increase the need for insulin.
The transition from one type of insulin to another should be carried out under the control of blood glucose levels.

The drug reduces tolerance to alcohol.
Due to the possibility of precipitation in some catheters, the use of the drug in insulin pumps is not recommended.

Impact on the ability to drive vehicles and operate machinery
In connection with the primary prescription of insulin, a change in its type, or in the presence of significant physical or mental stress, there may be a decrease in the ability to drive a car or operate various mechanisms, as well as engage in other potentially hazardous activities that require increased attention and speed of mental and motor reactions.

Injection technique when using insulin in vials

1. If the patient uses only one type of insulin
Disinfect the rubber membrane on the bottle.
Fill the syringe with air in an amount corresponding to the required dose of insulin. Inject air into the insulin vial.
Turn the bottle with the syringe upside down and draw the required dose of insulin into the syringe. Remove the needle from the vial and remove air from the syringe. Check that the insulin dose is set correctly.
Give the injection immediately.
2. If the patient needs to mix two types of insulin
Disinfect the rubber membranes on the bottles.
Immediately before drawing, roll the vial of long-acting insulin (“cloudy”) between your palms until the insulin becomes uniformly white and cloudy.

Fill the syringe with air in an amount corresponding to the dose of “cloudy” insulin. Inject air into the vial with “cloudy” insulin and remove the needle from the vial (“do not draw cloudy” insulin at this stage yet).

Fill the syringe with air in an amount corresponding to the dose of short-acting (“transparent”) insulin. Inject air into the vial of clear insulin. Turn the bottle with the syringe upside down and draw the required dose of “transparent” insulin. Remove the needle and remove air from the syringe. Check the correct dose.

Insert the needle into the vial with “cloudy” insulin, turn the vial with the syringe upside down and draw the required dose of insulin. Remove air from the syringe and check that the dose is correct. Inject the collected insulin mixture immediately.

Always draw insulins in the same sequence described above.

Injection technique when using insulin cartridges

The cartridge with the drug Biosulin® R is intended for use only with the Biomatic ®Pen or Biosulin ®Pen syringe pen. The patient should be warned about the need to carefully follow the instructions in the instructions for using the syringe pen for administering insulin.

Before use, make sure that there is no damage (for example, cracks) on the cartridge with Biosulin® R. Do not use the cartridge if there is any visible damage. After the cartridge is inserted into the pen, a colored stripe should be visible through the window of the cartridge holder.

After injection, the needle should remain under the skin for at least 6 seconds. You should keep the button pressed until the needle is completely removed from under the skin, thus ensuring the correct administration of the dose and limiting the possibility of blood or lymph getting into the needle or into the insulin cartridge.

The cartridge with Biosulin® R is intended for individual use only and cannot be refilled.

Injection procedure

Using two fingers, take a fold of skin, insert the needle into the base of the fold at an angle of about 45° and inject insulin under the skin.
After injection, the needle must remain under the skin for at least 6 seconds to ensure that the insulin is completely injected.

If blood appears at the injection site after removing the needle, apply light pressure to the injection site with your finger.
It is necessary to change injection sites.

Active ingredient

Insulin soluble human genetically engineered

Composition

1 ml of Biosulin R contains:

– genetically engineered human insulin – 100 IU;

Excipients:

metacresol,

glycerol,

water for injections.

Note:

To adjust the pH, a solution of sodium hydroxide or a 10% solution of hydrochloric acid is used.

Contraindications

Increased individual sensitivity to insulin or any of the components of the drug.
Hypoglycemia.

Side Effects

Caused by the effect on carbohydrate metabolism: hypoglycemic conditions (pallor of the skin, increased sweating, palpitations, tremor, hunger, agitation, paresthesia in the mouth, headache). Severe hypoglycemia can lead to the development of hypoglycemic coma.

Allergic reactions: rarely – skin rash, angioedema, extremely rarely – anaphylactic shock.

Local reactions: hyperemia, swelling and itching at the injection site, with long-term use – lipodystrophy at the injection site.

Other – edema, transient refractive errors (usually at the beginning of therapy).

Interaction

There are a number of medications that affect the need for insulin.

The hypoglycemic effect of insulin is enhanced by oral hypoglycemic drugs, monoamine oxidase inhibitors, angiotensin-converting enzyme inhibitors, carbonic anhydrase inhibitors, non-selective beta-blockers, bromocriptine, octreotide, sulfonamides, anabolic steroids, tetracyclines, clofibrate, ketoconazole, mebendazole, pyridoxine, theophylline, cyclophosphamide, fenfluramine, lithium preparations, preparations containing ethanol.

The hypoglycemic effect of insulin is weakened by oral contraceptives, glucocorticosteroids, thyroid hormones, thiazide diuretics, heparin, tricyclic antidepressants, sympathomimetics, danazol, clonidine, calcium channel blockers, diazoxide, morphine, phenytoin, nicotine.

Under the influence of reserpine and salicylates, it is possible to both weaken and enhance the effect of the drug.

Overdose

In case of overdose, hypoglycemia may develop.

Treatment: the patient can eliminate mild hypoglycemia himself by ingesting sugar or carbohydrate-rich foods. Therefore, patients with diabetes are recommended to constantly carry sugar, sweets, cookies or sweet fruit juice with them.

In severe cases, when the patient loses consciousness, a 40% dextrose solution is administered intravenously; intramuscularly, subcutaneously, intravenously – glucagon. After regaining consciousness, the patient is advised to eat a meal rich in carbohydrates to prevent the recurrence of hypoglycemia.

Manufacturer

Pharmstandard-UfaVITA, Russia